Keywords: corvas, rnapc2, promising, anticoagulant, phase, reacquires, rights
Corvas' rNAPc2 a promising anticoagulant in Phase I, reacquires rights to
Article | 11 March 1999
- A Phase I trial of Corvas' recombinant nematode anticoagulantprotein c2, a factor VIIa/tissue factor inhibitor derived from hookworms, demonstrated ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
